Perthera is the leading company advancing precision Oncology through the Perthera Precision Oncology Platform, which matches patients with cancer with therapy options that are ranked by the probability of a response.
Almost a decade ago, a group of Oncology, bioinformatics, and scientific research experts from both the National Cancer Institute and prestigious hospitals and universities joined together to create a company to explore the full potential and promise of precision Oncology. This team understood that genomic testing alone provides only one part of a very complex puzzle. They knew that, for patients to truly benefit, the entire range of multi-omic molecular data and the patient’s personal cancer history needed to be combined to give a more complete picture of the patient, their cancer, and the therapy that would provide the best possible outcome. This level of data collection is not routinely considered or reported in standard testing lab reports.
The result of their efforts is Perthera, Inc., and the revolutionary product is the Perthera Precision Oncology Platform which produces the Perthera Report.
A George Mason researcher, Emanuel “Chip” Petricoin, helped found Perthera Inc. which uses the latest science and technology to match cancer treatments to individual patients using their cancer’s molecular profile. This process is known as precision Oncology. The company has received major support from from Pilot Growth Equity, a technology growth equity firm that sees great potential in this technology.
“Such innovation, which was once isolated to the lab, is now creating opportunities for successful businesses that solve serious problems and generate economic growth.”
Perthera is a pioneer in using Multi-Omic testing results (DNA, RNA, IHC, and phosphoproteomics) to advise doctors and patients on treatment options through our Precision Oncology Platform and the Perthera Report it generates. We collect, or help doctors and patients obtain, multi-omic results from any source and use our Precision Oncology Platform to identify the best treatments available for each patient by applying the power of our proprietary Ranked Therapy Options process. The Perthera ranked therapy options, and Precision Oncology Platform that creates them, have been validated through publications in peer-reviewed high-impact journals and have been shown clinically to increase survival rates for those patients with pancreatic cancer who had actionable findings and followed its matched therapies. We are determined to make Perthera’s Precision Oncology Platform and the Perthera Report the best resource available today for Oncologists in their treatment decision-making process. Perthera’s clients and partners include the Mayo Clinic, Pfizer, AstraZeneca, Novartis, the Department of Defense, and many others.